Unlocking the Secrets of the Gut: How Multi-Omics is Revolutionizing IBD Research

By Michael Hamilton

There is a certain irony in how the human gut, an organ so essential to our survival, can also be a source of immense suffering. As someone living with a gastrointestinal condition, I know firsthand how unpredictable and disruptive these diseases can be. Simple daily activities become a strategic game of managing symptoms. This personal struggle is what drew me toward the medical subfield of gastroenterology. Beyond my own experience, I have seen how more serious conditions like Crohn's disease and ulcerative colitis (collectively known as inflammatory bowel diseases, or IBD) can take an even greater toll, limiting one's ability to live without the constant worry of an impending flare-up. In fact, it is estimated that over 1.5 million people in North America and 2 million people in Europe live with these diseases,[1] costing the average patient roughly $13,000 in annual expenses.[2] This economic burden underscores the urgency of advancing gastroenterological research. By improving diagnostic precision and enabling more targeted therapies, multi-omics has the potential to reduce costly and time-consuming trial-and-error treatment approaches, hospitalizations, and ineffective medication use, ultimately alleviating both personal and systemic healthcare costs.

While researchers have long searched for ways to better diagnose, treat, and even prevent these diseases, the complexity of the gut microbiome, home to trillions of microbes, has been a significant roadblock. The microbiome is an ecosystem that interacts with our immune system, our intestinal lining, and external factors like lifestyle. Historically, understanding this intricate interplay between the microbiome and its environment has been difficult, especially with conventional research methods that focused on simply one type of biological data at a time, such as genes, proteins, or metabolites. Multi-omics overcomes this limitation by integrating these diverse biological 'layers' into a unified, high-resolution view of the gut's biological landscape. By combining metagenomics (which identifies microbial species and the genes they carry that suggest their potential biological functions), transcriptomics (which tracks active gene expression), metabolomics (which measures biochemical byproducts of microbial activity), and proteomics (which catalogues proteins involved in inflammation and immune response), multi-omics allows researchers to see both the microbiome's composition and its functional impact on gut health. This comprehensive approach has already begun to yield novel biomarkers, which are biological molecules found in bodily fluids or tissues that can act as a sign of normal or abnormal processes.[3] With the advent of machine learning algorithms, researchers are now able to integrate these vast datasets to uncover previously hidden patterns, paving the way for precision medicine in IBD.

From Gut Feeling to Hard Science: What is Multi-Omics?

For decades, scientists have attempted to untangle the intricate relationship between the gut microbiome and IBD using individual research methods, such as genetic analysis or microbiome sequencing. However, these siloed approaches often fall short in capturing the full picture. Multi-omics, on the other hand, integrates multiple layers of biological data, including:

- **Genomics** – Investigating DNA sequences that may predispose individuals to IBD.
- **Metagenomics** – Sequencing microbial communities in the gut to understand which bacteria are present.
- **Transcriptomics** – Analyzing RNA to see which genes (both human and microbial) are actively being expressed.
- **Proteomics** – Examining proteins to identify inflammation markers or disease-related dysfunctions.
- **Metabolomics** – Measuring metabolites (small molecules involved in metabolism) to assess the gut's biochemical environment.

By layering these datasets together, researchers can pinpoint novel biomarkers. In simpler terms, multi-

https://doi.org/10.29173/hsi494
Received 28 March 2025
Accepted 1 July 2025

omics allows scientists to track not just which bacteria are in the gut, but also what they are doing and how it affects the host.

FeelingThe Power of Biomarkers: Predicting IBD Before it Strikes

Imagine a future where doctors can detect IBD before symptoms even appear, offering early interventions that prevent severe disease progression. Multi-omics is making this a real possibility. One groundbreaking study analyzed blood samples from individuals who later developed Crohn's disease, revealing a distinct pre-diagnostic protein signature up to five years before their official diagnosis.[4] This was achieved through proteomic analysis, where researchers examined thousands of proteins in the blood plasma of patients, comparing those who eventually developed Crohn's disease with healthy controls. They identified key inflammatory proteins and immune-related markers that were elevated long before any clinical symptoms appeared, indicating that systemic inflammation and immune activation may precede gut-specific symptoms by several years.

Another study utilized multi-omics by integrating metagenomics, metabolomics, and transcriptomics to assess the gut microbiome's role in predicting IBD flares.[5] By analyzing stool samples from patients over time, researchers discovered that subtle shifts in microbial gene expression and metabolite production correlated with upcoming disease activity. For example, a reduction in short-chain fatty acid-producing bacteria and an increase in pro-inflammatory microbial pathways were observed in patients who later experienced flares. These findings indicate that IBD isn't a sudden onset disease; rather, it follows a long, silent trajectory that multi-omics can help unveil, allowing for earlier intervention.

Adult IBD patients are not the only patients that can benefit from multi-omics research. In 2017, a study utilizing pediatric IBD patients revealed that distinct gene expression profiles at the time of diagnosis could predict whether they would develop complications like strictures or fistulas.[6] This study integrated transcriptomic, proteomic, and metagenomic data from intestinal biopsies and blood samples of newly diagnosed pediatric patients. By analyzing gene expression patterns within the intestinal mucosa, researchers identified upregulation of fibrosis-related pathways in children who later developed strictures, while inflammatory cytokine signalling was predominant in those who progressed to penetrating disease.

This insight is invaluable. High-risk patients might receive more aggressive therapy early on, such as biologics that target inflammatory pathways aligned with their predicted disease course. Meanwhile, low-risk individuals could potentially avoid unnecessary medications such as tricyclic antidepressants or chloride channel modifiers.[7] Tricyclics are often used off-label to manage gut-related pain but can cause side effects like excessive drowsiness and dry mouth. Chloride channel modifiers, typically prescribed for IBS-related constipation, may offer little benefit to IBD patients experiencing diarrhea-predominant symptoms. In parallel, multi-omics approaches have revealed microbial imbalances[8] that correlate with disease complications, suggesting that specific bacterial species may contribute to disease progression. These findings emphasize the power of multi-omics not only in identifying prognostic biomarkers but also in uncovering insights into the biological mechanisms by which IBD complications develop.

Moving Beyond Trial-and-Error Medicine

One of the biggest frustrations for IBD patients is the trial-and-error nature of current treatments. Some respond well to biologic therapies, while others endure months (or years) of failed treatments before finding relief. This unpredictability stems from the fact that IBD is not a singular disease but a spectrum of disorders with unique underlying biological mechanisms in each patient.[9] Traditional treatment approaches often fail to account for these individual differences, leading to prolonged suffering and unnecessary exposure to ineffective drugs.

Multi-omics is revolutionizing this approach by identifying biomarkers that predict drug response, enabling a more personalized treatment strategy. By integrating genomic, transcriptomic, and proteomic data, researchers can determine which patients are most likely to respond to specific therapies. For example, genomic sequencing has revealed that patients with specific NOD2 mutations have different responses to common anti-TNF agents such as infliximab and adalimumab.[10] Proteomic analysis has also shown that elevated levels of Oncostatin M, a secreted cytokine involved in chronic inflammation in intestinal tissues, correlate with poor response to biologics.[11,12] This means that before even

prescribing a medication, clinicians can now assess whether a patient has a molecular profile that suggests they will, or will not, respond to a given treatment.

Multi-omics also allows researchers to track real-time treatment responses by analyzing dynamic changes in gut microbial composition and host immune activation over time. Evidence from a recent metabolomic study suggests the presence of specific microbial metabolites, such as branched-chain amino acids, correlated with successful remission following biologic therapy.[13] These findings suggest that changes in microbial metabolite production may not only reflect treatment response but also influence it. As a result, therapies that directly target the gut microbiome – such as dietary interventions or probiotic supplementation – could potentially enhance the effectiveness of conventional drugs when used in combination.

The Future of Multi-Omics in IBD Research

Despite its immense promise, multi-omics still faces challenges. The technology is expensive, with one study indicating that it costs a staggering $12,743 for annual genomic and preliminary testing for pediatric oncology patients.[14] Additionally, while multi-omics has identified hundreds of potential IBD biomarkers, only a few have been clinically validated.[15] More large-scale, longitudinal studies are needed to translate these findings into everyday medical practice. However, the future is bright. Researchers are already exploring AI-driven multi-omics models that can integrate complex datasets and generate precise disease predictions.[16] Additionally, as sequencing costs decrease[17], multi-omic profiling may become a routine part of IBD diagnosis and treatment planning. For individuals living with IBD, this research represents something far greater than scientific progress; it offers hope. Hope for earlier diagnoses, personalized treatments, and perhaps one day, the ability to prevent these diseases altogether. The gut may still hold many secrets, but thanks to multi-omics, we are closer than ever to unlocking them.

Michael Hamilton is a first year Master's student in the department of Biochemistry and Biomedical Sciences. He studies the evolution of regulatory behaviours in bacteriophages and is applying this to the field of human gut microbiology.

References

1. Jairath, V. & Feagan, B. G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 5, 2–3 (2020).
2. Buono, J. L., Mathur, K., Averitt, A. J. & Andrae, D. A. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. J. Manag. Care Spec. Pharm. 23, 10.18553/jmcp.2016.16138 (2017).
3. Strimbu, K. & Tavel, J. A. What are Biomarkers? Curr. Opin. HIV AIDS 5, 463 (2010).
4. Torres, J. et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology 159, 96–104 (2020).
5. Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
6. Kugathasan, S. et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet Lond. Engl. 389, 1710 (2017).
7. Lacy, B. E., Weiser, K. & De Lee, R. The Treatment of Irritable Bowel Syndrome. Ther. Adv. Gastroenterol. 2, 221–238 (2009).
8. Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
9. Ramos, G. P. & Papadakis, K. A. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin. Proc. 94, 155–165 (2019).
10. HUMIRA (adalimumab), Abbott Laboratories - Package Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/adalabb123102lb.htm.
11. West, N. R. et al. Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579 (2017).
12. Verstockt, S. et al. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm. Bowel Dis. 27, 1564 (2021).
13. Ananthakrishnan, A. N. et al. Gut microbiome function predicts response to anti-integrin biologic therapy in Inflammatory Bowel diseases. Cell Host Microbe 21, 603 (2017).
14. Owens, C. E. L. et al. The economic costs of precision medicine for clinical translational research among children with high-risk cancer. NPJ Precis. Oncol. 8, 224 (2024).
15. Clough, J. et al. Biomarkers in inflammatory bowel disease: a practical guide. Ther. Adv. Gastroenterol. 17, 17562848241251600 (2024).
16. Sedano, R. et al. Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review. Ther. Adv. Gastroenterol. 18, 17562848251321915 (2025).
17. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) Available at: www.genome.gov/sequencingcostsdata. Accessed June 27, 2025.